JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
SK Biopharmaceutical is eyeing a share of the 4 trillion won US antiepileptic drug market with its cenobamate tablet Xcopri, which treats partial-onset seizures in adults.
The drug, approved by the US Food and Drug Administration (FDA) on November 21 last year, provides an extra needed treatment option for people with seizures.
Xcopri is the first Korean novel drug, researched and developed entirely and independently by a Korean pharma firm, notes SK Biopharmaceutical CEO Cho.
It is a product of Cho's 15-year research and development drive.
According to the US FDA, the safety and efficacy of XCOPRI were established in two studies that enrolled 655 adults, which were randomized, double-blind, and placebo-controlled.
The FDA granted Xcopri's approval to SK Life Science Inc., the US arm of SK Biopharmaceutical.
Thus, SK Life Science will undertake the US distribution of Xcopri.
